For US Healthcare Professionals
I am a:
Early diagnosis plays a vital role in addressing the needs of patients with active PsA, who may go overlooked and undertreated1
Up to 30% of patients with PsO go on to develop active PsA in the US population2
Patients with scalp and nail PsO have an increased risk of developing PsA1,3
Signs of structural damage in active PsA can begin prior to patients experiencing symptoms and may include enthesitis in lower limbs, abnormal bony projections at entheses, and bone erosions caused by chronic synovitis and osteoclast activation4,5
Diagnostic delay of more than 6 months can contribute to poor radiographic and functional outcomes in psoriatic arthritis6
References: 1. Scher JU, Ogdie A, Merola JF, et al. Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. Nat Rev Rheumatol. 2019;15(3):153-166. 2. Mease PJ, Liu C, Siegel E, et al. Impact of clinical specialty setting and geographic regions on disease management in patients with psoriatic arthritis in the United States: a multicenter observational study. Am J Clin Dermatol. 2019;20(6):873-880. 3. Perez-Chada LM, Elman S, Villa-Ruiz C, et al. Psoriatic arthritis: a comprehensive review for the dermatologist part I: epidemiology, comorbidities, pathogenesis, and diagnosis. J Am Acad Derm. 2025;92(5):969-982. 4. Sakkas LI, Alexiou I, Simopoulou T, et al. Enthesitis in psoriatic arthritis. Semin Arthritis Rheum. 2013;43(3):325-334. 5. Merola JF, Chakravarty S, Choi O, et al. A clinical review of structural damage in psoriatic arthritis for dermatologists: from pathogenesis to ongoing controversies. J Am Acad Dermatol. 2024;90(2):349-357. 6. Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis. 2015;74(6):1045-1050.
FOR ADULT PATIENTS WITH ACTIVE PsA
The road to APEX: Prior study showed a reduction in structural damage damage progression, although it was not statistically significant1
DISCOVER 2: Change from baseline in mvdH-S score: Blinded, placebo-controlled (Week 24)
The results are not statistically significant; therefore, treatment effect for inhibition of structural damage has not been established.
Patients received TREMFYA® 100 mg SC at Week 0, Week 4, and every 8 weeks thereafter.
Treatment failure rules were not applied, and missing data were assumed to be missing at random and were imputed using multiple imputation.
LS=least squares; mvdH-S=modified van der Heijde-Sharp; NS=not significant; PsA=psoriatic arthritis; SC=subcutaneous.
*P value is not significant.
Reference: 1. Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naïve patients with active psoriatic arthritis (DISCOVER 2): a double-blind, randomized, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1126-1136.
FOR YOUR ADULT PATIENTS WITH ACTIVE PsA
APEX: ACR20/50/70 responses:APEX: ACR20/50/70
responses: Blinded, placebo-controlled
(Week 24)1,2*
ACR50 and ACR70 responses at Week 24 were not adjusted for multiplicity; therefore, statistical significance has not been established.
Primary endpoint in pivotal studies: At Week 24, adult patients with active PsA receiving TREMFYA® demonstrated a greater clinical response in ACR20 compared to placebo, in both the DISCOVER 1 (52% vs 22%) and DISCOVER 2 (64% vs 33%) trials, respectively (P<0.0001).3-5
ACR=American College of Rheumatology; CI=confidence interval; CMH=Cochran-Mantel-Haenszel; mFAS=modified full analysis set; PsA=psoriatic arthritis.
*Efficacy analyses are from the mFAS, which included all randomized patients, excluding those from Ukraine sites rendered unable to support key study operations due to major disruptions.
†The primary endpoint P value is multiplicity controlled using a fixed sequence testing procedure and can be used to determine statistical significance. Statistics are based on the CMH test across multiply imputed datasets.
Reference: 1. Mease PJ, Ritchlin CT, Coates LC, et al. Inhibition of structural damage progression with guselkumab, a selective IL-23i, in participants with active PsA: results through Week 24 of the phase 3b, randomized, double-blind, placebo-controlled APEX study. Oral presentation at: European Alliance of Associations for Rheumatology (EULAR) 2025 Congress; June 11-14, 2025; Barcelona, Spain. 2. Mease PJ, Ritchlin CT, Coates LC, et al. Inhibition of structural damage progression with guselkumab, a selective IL-23i, in participants with active PsA: results through Week 24 of the phase 3b, randomized, double blind, placebo-controlled APEX study. Abstract presented at: European Alliance of Associations for Rheumatology (EULAR) 2025 Congress; June 11-14, 2025; Barcelona, Spain. Late-Breaking Abstracts Session II. 3. TREMFYA® (guselkumab) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 4. Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naïve patients with active psoriatic arthritis (DISCOVER 2): a double-blind, randomized, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1126-1136. 5. Deodhar A, Helliwell PS, Boehncke W-H, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER 1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1115-1125.
GIVE YOUR ADULT PATIENTS WITH ACTIVE PsA THE CHANCE FOR
Joint preservation with TREMFYA®1,2
Significant (2.5x) reduction in structural damage progression vs placebo
APEX: Change in total mvdH-S score: Blinded, placebo-controlled (Week 24)*†
ANCOVA=analysis of covariance; ND/MD=natural disaster/
major disruption.
*Efficacy analyses are from the mFAS, which included all randomized patients, excluding those from Ukraine sites rendered unable to
support key study operations due to major disruptions.
†Statistics are based on ANCOVA. Missing data and data impacted by ND/MD were imputed using multiple imputation.
‡Major secondary endpoint P value is multiplicity controlled using a fixed sequence testing procedure and can be used to determine
statistical significance. Statistics are based on ANCOVA across multiply imputed datasets.
APEX: Erosion and joint space narrowing scores with TREMFYA® at Week 241,2*†‡
†Erosion score and JSN score at Week 24 were not adjusted for multiplicity; therefore, statistical significance has not been established.
‡Based on ANCOVA of multiply imputed data.
JSN=joint space narrowing.
*Efficacy analyses are from the mFAS, which included all randomized patients, excluding those from Ukraine sites rendered unable to support key study operations due to major disruptions.
References: 1. Mease PJ, Ritchlin CT, Coates LC, et al. Inhibition of structural damage progression with guselkumab, a selective IL-23i, in participants with active PsA: Results through Week 24 of the phase 3b, randomized, double-blind, placebo-controlled APEX study. Oral presentation at: European Alliance of Associations for Rheumatology (EULAR) 2025 Congress; June 11-14, 2025; Barcelona, Spain. 2. Mease PJ, Ritchlin CT, Coates LC, et al. Inhibition of structural damage progression with guselkumab, a selective IL-23i, in participants with active PsA: Results through Week 24 of the phase 3b, randomized, double-blind, placebo-controlled APEX study. Abstract presented at: European Alliance of Associations for Rheumatology (EULAR) 2025 Congress; June 11-14, 2025; Barcelona, Spain. Late-Breaking Abstracts Session II.
IN ADULT PATIENTS WITH MODERATE TO SEVERE PLAQUE PsO
